USFDA Approves Crofelemer 125 mg Delayed-release Tablets for the … – PR Newswire (press release)

USFDA Approves Crofelemer 125 mg Delayed-release Tablets for the
PR Newswire (press release)
In addition, statistically significant reductions from baseline to the end of the double-blind period also were observed for the number of watery bowel movements per day, and daily stool consistency score, among patients taking Crofelemer compared with

and more »

View full post on world asthma day – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *